<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22247720</article-id><article-id pub-id-type="pmc">3252771</article-id><article-id pub-id-type="publisher-id">JRMS-16-361</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of eicosapentaenoic acid and vitamin C on glycemic indices, blood pressure, and serum lipids in type 2 diabetic Iranian males</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mahmoudabadi</surname><given-names>Mohammad Mehdi Shakouri</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Djalali</surname><given-names>Mahmoud</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Djazayery</surname><given-names>Seyed Abolghassem</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Keshavarz</surname><given-names>Seyed Ali</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Eshraghian</surname><given-names>Mohammad Reza</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Yaraghi</surname><given-names>Ali Akbar Saboor</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Askari</surname><given-names>Gholamreza</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Ghiasvand</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Zarei</surname><given-names>Mahnaz</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib></contrib-group><aff id="aff1"><label>a</label> Department of Nutrition and Biochemistry, School of Public Health, Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="aff2"><label>b</label> Department of Biostatistics and Epidemiology, School of Public Health, Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="aff3"><label>c</label> Department of Nutrition, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><author-notes><corresp id="cor1"><label>*</label> Corresponding Author E-mail: <email xlink:href="mjalali87@yahoo.com">mjalali87@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2011</year></pub-date><volume>16</volume><issue>Suppl1</issue><fpage>S361</fpage><lpage>S367</lpage><history><date date-type="received"><day>12</day><month>12</month><year>2010</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>BACKGROUND:</title><p>Eicosapentaenoic acid (EPA) is the principal &#x003c9;-3 fatty acids in marine oils. Fasting blood sugar (FBS), HbA1c and some of the plasma lipids and lipoproteins has been negatively related to the intake of &#x003c9;-3 fatty acids and ascorbic acid, in some studies. Therefore, the purpose of this study was to assess the effects of EPA and/or vitamin C on glycemic indices, blood pressure, and plasma lipids in type 2 diabetic Iranian males.</p></sec><sec id="st2"><title>METHODS:</title><p>Sixty five men with type 2 diabetes were enrolled into the study between April 2 and June 27, 2008. Venous blood samples were obtained from all participants after 10 hours of fasting, at the baseline and after the intervention. Subjects received 500 mg EPA and/or 200 mg vitamin C and/or placebo depending on their groups. For eight weeks, 15 participants received EPA supplements with vitamin C (group 1), 16 took EPA supplements and vitamin C placebo (group 2), 17 took EPA placebo and vitamin C (group 3), and 17 received EPA placebo and vitamin C placebo (group 4), daily.</p></sec><sec id="st3"><title>RESULTS:</title><p>There were significant decreases in FBS, HbA1C, LDL-C and TG in groups 1, 2, 3 and 4 (p &#x0003c; 0.01), but significant decreases in TC were shown only in groups 1, 2 and 3 (p &#x0003c; 0.01). There was a significant increase in HDL-C in all groups (p &#x0003c; 0.01).</p></sec><sec id="st4"><title>CONCLUSIONS:</title><p>In summary, it is concluded that, eight weeks of taking EPA + vitamin C supplementation improved the plasma levels of cardiovascular markers but didn&#x02019;t reduce BP.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>Eicosapentaenoic Acid</kwd><kwd>Ascorbic Acid</kwd><kwd>Fasting</kwd><kwd>Blood Glucose</kwd><kwd>HbA1C</kwd><kwd>Glycosylated</kwd><kwd>Lipids</kwd><kwd>Blood Pressure</kwd><kwd>Diabetes Mellitus</kwd></kwd-group></article-meta></front><body><p>Diabetes is a common chronic disease and a serious medical and social problem. Diabetic men and women have over a 1.5 and 2.5 times risk of cardiovascular disease (CVD) in Iran, respectively.<xref ref-type="bibr" rid="ref1">1</xref></p><p>Eicosapentaenoic acid (EPA; 22:5n-3) is the principal &#x003c9;-3 fatty acids in fish oils. Recent evidence demonstrated that this fatty acid have different effects on plasma glucose,<xref ref-type="bibr" rid="ref2">2</xref> serum lipids and lipoproteins,<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref> and blood pressure.<xref ref-type="bibr" rid="ref4">4</xref></p><p>EPA supplementation increased insulin sensitivity in animal models and in some human studies,<xref ref-type="bibr" rid="ref5">5</xref> therefore fasting blood sugar and HbA1c has been negatively correlated with intake of &#x003c9;-3 fatty acids, in some studies.<xref ref-type="bibr" rid="ref6">6</xref> Results of some prospective studies, however, did not show a relation.<xref ref-type="bibr" rid="ref7">7</xref></p><p>On the other hand, some reports from few studies, however, raised the possibility of an adverse effect of high doses of fish oils on glycemic control in type 2 diabetes.<xref ref-type="bibr" rid="ref8">8</xref></p><p>However, there are significant evidences for a beneficial effect of dietary &#x003c9;-3 fatty acids in the prevention of heart disease,<xref ref-type="bibr" rid="ref9">9</xref> in high-risk populations, especially.<xref ref-type="bibr" rid="ref10">10</xref></p><p>Insulin resistance, hyperlipidemia and hypertension are major metabolic disorders in patients with type 2 diabetes and therefore these patients have an increased risk of cardiovascular diseases.<xref ref-type="bibr" rid="ref11">11</xref></p><p>Consequently, some experts discourage the use of &#x003c9;-3 fatty acids in type 2 diabetic patients, whereas others encourage such use, although at low doses.</p><p>The different studies in the past decade indicated that diabetes is associated with oxidative stress. It is therefore possible that dietary supplementation with antioxidants would be useful.<xref ref-type="bibr" rid="ref12">12</xref></p><p>The diabetes may increase free radicals generation. However, incorporation of the highly unsaturated fatty acids in membranes may increase the membranes&#x02019; susceptibility to lipid peroxidation.<xref ref-type="bibr" rid="ref13">13</xref> Vitamin C is reported to decrease diabetes induced lipid peroxidation.<xref ref-type="bibr" rid="ref14">14</xref> To this time, no study has been done to assess the effects of supplementation with EPA and/or vitamin C on cardiovascular risk factors in type 2 diabetic patients. The purpose of this study was to evaluate the effects of EPA and/or vitamin C on glycemic indices, blood pressure, and serum lipids in type 2 diabetic Iranian males.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>In this randomized double blind placebo controlled clinical trial, 65 men with type 2 diabetes, aged 33-63 years, were enrolled into the study between April 2 and June 27, 2008. Ethical approval was obtained from the Medical Ethics Committee of Tehran University of Medical Sciences and informed consent was obtained from all individuals. The participants were instructed not to take any &#x003c9;-3 fatty acids and antioxidant supplements during, and 2 weeks preceding the study. Exclusion criteria included onset of nephropathy, myocardial infarction, coronary bypass grafting and inflammatory diseases.</p><p>Venous blood samples were obtained from all participants at 8:00-9:00 A.M., after 10 hours of fasting, at the baseline and after intervention. Subjects received 500 mg EPA and/or 200 mg vitamin C or placebo depending on their groups. For a period of 8 weeks, 15 participants received daily EPA supplements with vitamin C (group 1), 16 took EPA supplements and vitamin C placebo (group 2), 17 took EPA supplement placebo and vitamin C (group 3), and 17 received EPA supplement placebo and vitamin C placebo (group 4). EPA and EPA placebo soft gels were supplied from Minami Nutrition (Belgium). The vitamin C and their placebo soft gels were obtained from Darou Pakhsh Pharma Chem. Co. (Iran).</p><p>Plasma glucose was determined by a glucose analyzer (YSI, Yellow Springs, OH). HbA1c levels were measured by immuneturbidimetric immunoassay (Unimate; Roche Diagnostics, Indianapolis, IN) with a normal range of 4.5-6.1%. Serum TG and TC levels were determined using the enzymatic method. HDL-C levels were measured by the turbidimetric method.</p><p>LDL-cholesterol (LDL-c) was calculated using Friedwald's formula. Anthropometric indices included height and weight measured with a Seca standard tools. BMI was calculated from this formula: [weight (kg)/hight<sup>2</sup> (m)]. Blood pressure (BP) was measured twice in a seated position after 15 minutes of rest using a standard mercury sphygmomanometer.</p><p>Microsoft Excel was used for data handling and SPSS (version 10; SPSS Inc., Chicago, IL, USA) was used for statistical analysis . Values are expressed as means and standard errors for each group. The significant level was set at p &#x0003c; 0.05.</p></sec><sec id="sec1-2"><title>Results</title><p>Sixty-nine diabetic men with a mean age of 48 years (range: 33-63 years) were recruited. Sixty-five participants completed the 8-week intervention. Some of the participants&#x02019; characteristics are shown in <xref ref-type="table" rid="T1">table 1</xref>. Mean &#x000b1; SD plasma levels of FBS, HbA1C, TC, LDL-C, HDL-C, TG and BP are presented in <xref ref-type="table" rid="T2">table 2</xref>. There were significant decreases in FBS, HbA1C, LDL-C and TG in groups 1 (p &#x0003c; 0.01), 2 (p &#x0003c; 0.01), 3 (p &#x0003c; 0.01) and 4 (p &#x0003c; 0.01), but significant decreases in TC was shown in groups 1 (p &#x0003c; 0.01), 2 (p &#x0003c; 0.01) and 3 (p &#x0003c; 0.01), not in group 4. There was a significant increase in HDL-C in all groups (p &#x0003c; 0.01). There were significant differences in FBS between groups 1 and 2 (p &#x0003c; 0.05), groups 1 and 3 (p &#x0003c; 0.05) and groups 2 and 4 (p &#x0003c; 0.05). LDL-C was significantly different between group 1 and other groups (p &#x0003c; 0.01). There were significant differences in HDL-C level between group 3 and other groups (p &#x0003c; 0.05), and TG level was significantly different between groups 1 and 2 (p &#x0003c; 0.01), groups 2 and 3 (p &#x0003c; 0.05), groups 2 and 4 (p &#x0003c; 0.01), and groups 3 and 4 (p &#x0003c; 0.01), but no difference in HbA1C, TC and BP was seen between the groups after 8 weeks of intervention (<xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of subjects [mean (SD)]</p></caption><graphic xlink:href="JRMS-16-361-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparisons of parameters in the groups before and after 8 weeks of supplementation [mean (SD)]</p></caption><graphic xlink:href="JRMS-16-361-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Multiple comparisons of parameters among groups after 8 weeks of supplementation [mean (SD)]</p></caption><graphic xlink:href="JRMS-16-361-g003"/></table-wrap></sec><sec id="sec1-3"><title>Discussion</title><p>This randomized double-blind placebo controlled clinical trial in diabetic patients demonstrated a decrease in all variables in four groups except for TC in group 4 and an increase in HDL-C in all groups, although BP did not change in any group, following 8 weeks of supplementation. These results suggest that EPA with or without vitamin C can improve the cardiovascular markers in plasma, but alone or along with vitamin C cannot reduce the blood pressure. These findings are consistent with the results of some previous studies.<xref ref-type="bibr" rid="ref15">15</xref><xref ref-type="bibr" rid="ref16">16</xref> Others however, reported no effect or a harmful effect<xref ref-type="bibr" rid="ref17">17</xref> for increased &#x003c9;-3 fatty acid intake.</p><p>Potential mechanisms for the cardio-protective effects of &#x003c9;-3 fatty acids include anti-thrombotic, anti-inflammatory and anti-arrhythmic effects, as well as its effects on lowering blood pressure (BP), and reducing plasma triglycerides (TG) levels.<xref ref-type="bibr" rid="ref18">18</xref></p><p>In addition, higher EPA quantities in the phospholipid cell membranes could increase insulin sensitivity.<xref ref-type="bibr" rid="ref19">19</xref></p><p>Some studies showed that fish oil rich in EPA and DHA lowers blood pressure. Metaanalyses of controlled trials on fish oil supplementation suggested that the BP-lowering effect in hypertension is both dose- (&#x0003e; 3 g/d) and time-dependent.<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref></p><p>Many epidemiologic and interventional studies have assessed the relations and effects of the intake of &#x003c9;-3 fatty acids<xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref23">23</xref> on CVD biomarkers in a variety of populations. Healthy subjects and those at high risk for CHD, including diabetic patients and patients who had suffered a myocardial infarction (MI) have been evaluated. Many different study designs for both studies have been used. Reductions in CVD have been observed with two servings of fish per week, 1.8 g/day of EPA as an ethyl ester and 1 g/day of an 85% EPA + DHA concentrate in the form of an ethyl ester.<xref ref-type="bibr" rid="ref24">24</xref><xref ref-type="bibr" rid="ref25">25</xref></p><p>The results of the present study also showed significant differences in FBS between groups 1 and 2 (p &#x0003c; 0.05), groups 1 and 3 (p &#x0003c; 0.05) and groups 2 and 4 (p &#x0003c; 0.05). Furthermore, there were significant differences in LDL-C between group 1 and other groups (p &#x0003c; 0.01). A significant difference in HDL-C was seen between group 3 and other groups (p &#x0003c; 0.05) and in TG between groups 1 and 2 (p &#x0003c; 0.01), groups 2 and 3 (p &#x0003c; 0.05), groups 2 and 4 (p &#x0003c; 0.01), and groups 3 and 4 (p &#x0003c; 0.01), too.</p><p>Individual fatty acids have large effects on physiologic functions that are determined by a collection of chain length, number and position of double bonds, and isomerism around these bonds. One of the possible mechanisms is that &#x003c9;-3 fatty acids vary from &#x003c9;-6 fatty acids in their effects on plasma lipids, BP, and other biomarkers of CVD risk such as lipoprotein (a), inflammatory markers, fasting plasma glucose and insulin, and clotting factors.<xref ref-type="bibr" rid="ref26">26</xref></p><p>In many studies, mechanisms potentially responsible for these effects have been examined. EPA constitutes part of the cell membrane, replacing other mostly unsaturated fatty acids there, and so modifying cellular function. Hence, a number of variations of cell function can be observed upon inclusion of EPA into the cell membrane. Among them are the shift of the eicosanoid system towards vasodilatation and less inflammation, a lowering of blood TG and anti-arrhythmic effects.<xref ref-type="bibr" rid="ref27">27</xref></p><p>Clinical trial data provide evidence on the favorable effects of &#x003c9;-3 fatty acids in reducing the risk of CHD. The GISSI-Prevention Trial is one of the largest clinical trials to test the efficacy of &#x003c9;-3 fatty acid supplementation for secondary prevention of CHD.<xref ref-type="bibr" rid="ref28">28</xref> The trial included 11,324 subjects with a recent MI who were assigned to either &#x003c9;-3 fatty acid supplements (850 mg/d), tocopherol (300 mg/d), both or none for 3.5 years along with a Mediterranean diet. The Mediterranean diet emphasizes less meat consumption with more bread, vegetables, fruit, and fish intake. &#x003c9;-3 fatty acid supplementation decreased all-cause death by 20% and stroke by 15%. On the other hand, evidence from three epidemiologic studies, the NHANES I Follow-up Study<xref ref-type="bibr" rid="ref29">29</xref> and the JPHC Study Cohort I<xref ref-type="bibr" rid="ref30">30</xref> did not show any significant decrease in CHD incidence with increasing intakes of fish.</p></sec><sec id="sec1-4"><title>Conclusion</title><p>In conclusion, this study showed that 8 weeks of taking EPA + vitamin C supplementation improved the plasma levels of cardiovascular markers but didn&#x02019;t reduce BP. Further studies are needed to confirm these results.</p></sec><sec id="sec1-5"><title>Authors&#x02019; Contributions</title><p>MMSM did the laboratory procedures and statistical analysis and prepared the first version of manuscript. MD has planned the study and finalized the manuscript. SAD, SAK, MRE, AASY, GA, and RG supervised the project with association of MD. MZ provided the help in the laboratory analysis.</p></sec></body><back><ack><p>This project was supported by the Vice-Chancellery for Research of Tehran University of Medical Sciences; Grant No. 7330.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Conflict of Interests</bold> Authors has no conflict of interests.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harati</surname><given-names>H</given-names></name><name><surname>Hadaegh</surname><given-names>F</given-names></name><name><surname>Saadat</surname><given-names>N</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran</article-title><source>BMC Public Health</source><year>2009</year><volume>9</volume><fpage>186</fpage><pub-id pub-id-type="pmid">19531260</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanjihia</surname><given-names>VW</given-names></name><name><surname>Kiplamai</surname><given-names>FK</given-names></name><name><surname>Waudo</surname><given-names>JN</given-names></name><name><surname>Boit</surname><given-names>MK</given-names></name></person-group><article-title>Post-prandial glucose levels and consumption of omega 3 fatty acids and saturated fats among two rural populations in Kenya</article-title><source>East Afr Med J</source><year>2009</year><volume>86</volume><issue>6</issue><fpage>259</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20358787</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuliani</surname><given-names>G</given-names></name><name><surname>Galvani</surname><given-names>M</given-names></name><name><surname>Leitersdorf</surname><given-names>E</given-names></name><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Cavalieri</surname><given-names>M</given-names></name><name><surname>Fellin</surname><given-names>R</given-names></name></person-group><article-title>The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias</article-title><source>Curr Pharm Des</source><year>2009</year><volume>15</volume><issue>36</issue><fpage>4087</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">20041810</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geleijnse</surname><given-names>JM</given-names></name><name><surname>Giltay</surname><given-names>EJ</given-names></name><name><surname>Schouten</surname><given-names>EG</given-names></name><name><surname>de Goede</surname><given-names>J</given-names></name><name><surname>Oude Griep</surname><given-names>LM</given-names></name><name><surname>Teitsma-Jansen</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial</article-title><source>Am Heart J</source><year>2010</year><volume>159</volume><issue>4</issue><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">20362710</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorseng</surname><given-names>T</given-names></name><name><surname>Witte</surname><given-names>DR</given-names></name><name><surname>Vistisen</surname><given-names>D</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Bjerregaard</surname><given-names>P</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>ME</given-names></name></person-group><article-title>The association between n-3 fatty acids in erythrocyte membranes and insulin resistance: the Inuit Health in Transition Study</article-title><source>Int J Circumpolar Health</source><year>2009</year><volume>68</volume><issue>4</issue><fpage>327</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19917185</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>T</given-names></name><name><surname>Yatsuya</surname><given-names>H</given-names></name><name><surname>Toyoshima</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>R</given-names></name><etal/></person-group><article-title>Higher dietary intake of alpha-linolenic acid is associated with lower insulin resistance in middle-aged Japanese</article-title><source>Prev Med</source><year>2010</year><volume>50</volume><issue>5-6</issue><fpage>272</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20211645</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>H</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Riddle</surname><given-names>MC</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name></person-group><collab>ORIGIN Trial Investigators</collab><article-title>Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)</article-title><source>Am Heart J</source><year>2008</year><volume>155</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><series>32.e1-6</series><pub-id pub-id-type="pmid">18082485</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olza</surname><given-names>J</given-names></name><name><surname>Mesa</surname><given-names>MD</given-names></name><name><surname>Aguilera</surname><given-names>CM</given-names></name><name><surname>Moreno-Torres</surname><given-names>R</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>A</given-names></name><name><surname>P&#x000e9;rez de la Cruz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Influence of an eicosapentaenoic and docosahexaenoic acid-enriched enteral nutrition formula on plasma fatty acid composition and biomarkers of insulin resistance in the elderly</article-title><source>Clin Nutr</source><year>2010</year><volume>29</volume><issue>1</issue><fpage>31</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19573960</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manerba</surname><given-names>A</given-names></name><name><surname>Vizzardi</surname><given-names>E</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Dei Cas</surname><given-names>L</given-names></name></person-group><article-title>n-3 PUFAs and cardiovascular disease prevention</article-title><source>Future Cardiol</source><year>2010</year><volume>6</volume><issue>3</issue><fpage>343</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20462340</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Origasa</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Matsuzaki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia</article-title><source>Circ J</source><year>2010</year><volume>74</volume><issue>3</issue><fpage>510</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20145342</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>C</given-names></name><name><surname>Penno</surname><given-names>G</given-names></name><name><surname>Miccoli</surname><given-names>R</given-names></name><name><surname>Del Prato</surname><given-names>S</given-names></name></person-group><article-title>Blood glucose control and coronary heart disease</article-title><source>Herz</source><year>2010</year><volume>35</volume><issue>3</issue><fpage>148</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">20467927</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassort</surname><given-names>G</given-names></name><name><surname>Turan</surname><given-names>B</given-names></name></person-group><article-title>Protective role of antioxidants in diabetes-induced cardiac dysfunction</article-title><source>Cardiovasc Toxicol</source><year>2010</year><volume>10</volume><issue>2</issue><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">20458637</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathod</surname><given-names>NR</given-names></name><name><surname>Raghuveer</surname><given-names>I</given-names></name><name><surname>Chitme</surname><given-names>HR</given-names></name><name><surname>Chandra</surname><given-names>R</given-names></name></person-group><article-title>Free radical scavenging activity of calotropis gigantea on strepto-zotocin-induced diabetic rats</article-title><source>Indian J Pharm Sci</source><year>2009</year><volume>71</volume><issue>6</issue><fpage>615</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20376213</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lautt</surname><given-names>WW</given-names></name><name><surname>Ming</surname><given-names>Z</given-names></name><name><surname>Legare</surname><given-names>DJ</given-names></name></person-group><article-title>Attenuation of age- and sucrose-induced insulin resistance and syndrome X by a synergistic antioxidant cocktail: the AMIS syndrome and HISS hypothesis</article-title><source>Can J Physiol Pharmacol</source><year>2010</year><volume>88</volume><issue>3</issue><fpage>313</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20393596</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degirolamo</surname><given-names>C</given-names></name><name><surname>Kelley</surname><given-names>KL</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Rudel</surname><given-names>LL</given-names></name></person-group><article-title>Dietary n-3 LCPUFA from fish oil but not alpha-linolenic acid-derived LCPUFA confers atheroprotection in mice</article-title><source>J Lipid Res</source><year>2010</year><volume>51</volume><issue>7</issue><fpage>1897</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">20154006</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cayli</surname><given-names>S</given-names></name><name><surname>Sati</surname><given-names>L</given-names></name><name><surname>Seval-Celik</surname><given-names>Y</given-names></name><name><surname>Tuncer</surname><given-names>MA</given-names></name><name><surname>Yaymaci</surname><given-names>B</given-names></name><name><surname>Berkman</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The effects of eicosapentaenoic acid on the endothelium of the carotid artery of rabbits on a high-cholesterol diet</article-title><source>Histol Histopathol</source><year>2010</year><volume>25</volume><issue>2</issue><fpage>141</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20017101</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Oikawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease</article-title><source>Circ J</source><year>2009</year><volume>73</volume><issue>7</issue><fpage>1283</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">19423946</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tziomalos</surname><given-names>K</given-names></name><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name></person-group><article-title>Omega-3 fatty acids: how can they be used in secondary prevention?</article-title><source>Curr Atheroscler Rep</source><year>2008</year><volume>10</volume><issue>6</issue><fpage>510</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18937899</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuda</surname><given-names>O</given-names></name><name><surname>Jelenik</surname><given-names>T</given-names></name><name><surname>Jilkova</surname><given-names>Z</given-names></name><name><surname>Flachs</surname><given-names>P</given-names></name><name><surname>Rossmeisl</surname><given-names>M</given-names></name><name><surname>Hensler</surname><given-names>M</given-names></name><etal/></person-group><article-title>n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><issue>5</issue><fpage>941</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">19277604</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MC</given-names></name><name><surname>Sacks</surname><given-names>F</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name></person-group><article-title>Does fish oil lower blood pressure? A meta-analysis of controlled trials</article-title><source>Circulation</source><year>1993</year><volume>88</volume><issue>2</issue><fpage>523</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8339414</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Ertek</surname><given-names>S</given-names></name><name><surname>Borghi</surname><given-names>C</given-names></name></person-group><article-title>Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management</article-title><source>Curr Vasc Pharmacol</source><year>2009</year><volume>7</volume><issue>3</issue><fpage>330</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19601857</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>EM</given-names></name><name><surname>Harris</surname><given-names>WS</given-names></name></person-group><article-title>Fish oil for primary and secondary prevention of coronary heart disease</article-title><source>Curr Atheroscler Rep</source><year>2010</year><volume>12</volume><issue>1</issue><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20425273</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>SK</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ojha</surname><given-names>SK</given-names></name><name><surname>Sharma</surname><given-names>SB</given-names></name></person-group><article-title>Cardiovascular friendly natural products: a promising approach in the management of CVD</article-title><source>Nat Prod Res</source><year>2010</year><volume>24</volume><issue>9</issue><fpage>873</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">20461632</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levitan</surname><given-names>EB</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Mittleman</surname><given-names>MA</given-names></name></person-group><article-title>Fatty fish, marine omega-3 fatty acids and incidence of heart failure</article-title><source>Eur J Clin Nutr</source><year>2010</year><volume>64</volume><issue>6</issue><fpage>587</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">20332801</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>TA</given-names></name><name><surname>Ambrosini</surname><given-names>G</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Oddy</surname><given-names>WH</given-names></name></person-group><article-title>Dietary intake and food sources of fatty acids in Australian adolescents</article-title><source>Nutrition</source><year>2010</year><month>3</month><day>23</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massaro</surname><given-names>M</given-names></name><name><surname>Scoditti</surname><given-names>E</given-names></name><name><surname>Carluccio</surname><given-names>MA</given-names></name><name><surname>Campana</surname><given-names>MC</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name></person-group><article-title>Omega-3 fatty acids, inflammation and angiogenesis: basic mechanisms behind the cardioprotective effects of fish and fish oils</article-title><source>Cell Mol Biol (Noisy-le-grand)</source><year>2010</year><volume>56</volume><issue>1</issue><fpage>59</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20196971</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allayee</surname><given-names>H</given-names></name><name><surname>Roth</surname><given-names>N</given-names></name><name><surname>Hodis</surname><given-names>HN</given-names></name></person-group><article-title>Polyunsaturated fatty acids and cardiovascular disease: implications for nutrigenetics</article-title><source>J Nutrigenet Nutrigenomics</source><year>2009</year><volume>2</volume><issue>3</issue><fpage>140</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19776641</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R</given-names></name><name><surname>Di Pasquale</surname><given-names>A</given-names></name></person-group><article-title>The biochemical, pharmacological and epidemiological reference picture of the GISSI-Prevention.The Gruppo Italiano per lo Studio della Streptochinasi nell&#x02019;Infarto Miocardico</article-title><source>G Ital Cardiol</source><year>1993</year><volume>23</volume><issue>9</issue><fpage>933</fpage><lpage>64</lpage><comment>(Italian)</comment><pub-id pub-id-type="pmid">8119523</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osler</surname><given-names>M</given-names></name><name><surname>Andreasen</surname><given-names>AH</given-names></name><name><surname>Hoidrup</surname><given-names>S</given-names></name></person-group><article-title>No inverse association between fish consumption and risk of death from all causes, and incidence of coronary heart disease in middle-aged, Danish adults</article-title><source>J Clin Epidemiol</source><year>2003</year><volume>56</volume><issue>3</issue><fpage>274</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12725883</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iso</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Ishihara</surname><given-names>J</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I</article-title><source>Circulation</source><year>2006</year><volume>113</volume><issue>2</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">16401768</pub-id></element-citation></ref></ref-list></back></article>